Scopus
EXPORT DATE: 2 October 2020

@ARTICLE{Buchner2019690,
author={Buchner, B. and Hase, F. and Borchers, D. and Pigeot, I.},
title={Tasks, regulations, and functioning of ethics committees [Aufgaben, Regularien und Arbeitsweise von Ethikkommissionen]},
journal={Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz},
year={2019},
volume={62},
number={6},
pages={690-696},
doi={10.1007/s00103-019-02945-7},
note={cited By 2},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065325197&doi=10.1007%2fs00103-019-02945-7&partnerID=40&md5=e0919c952288858f468bff6f6bec5a11},
affiliation={Universität Bremen, Institut für Informations‑, Gesundheits- und Medizinrecht (IGMR), Universitätsallee GW 1, Bremen, 28359, Germany; Universität Bremen, Institut für Philosophie, Bremen, Germany; Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS, Bremen, Germany; Universität Bremen, Fachbereich Mathematik und Informatik, Bremen, Germany},
abstract={Our constitutional order provides comprehensive protection of the freedom of scientific research; any interference with this freedom requires justification. With regard to the obligatory involvement of ethics committees in the research process, this justification is based on a careful balancing of scientific freedom on one hand and the legal interests of study participants, such as the protection of life, health, and self-determination, on the other. How this is achieved, and with what results, is shown below for two areas. The first of these are clinical trials in pharmaceutical and medicinal product law, which are subject to extensive regulations regarding the involvement of ethics committees. Following the amendments at European level, this area has been comprehensively restructured, in particular with regard to the function and importance of ethics committees. Subsequently, the role of ethics committees in university research is discussed as far as this research is not regulated by the German Medicines Act (AMG) and the German Act on Medical Devices (MPG), but instead is mostly subject to university self-government. It is shown, using statistics as an example, that a line must be drawn between legitimate control of scientific research and a sweeping “ethicization” of science. To conclude, this very boundary is examined from a philosophical perspective. © 2019, Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature.},
author_keywords={Clinical trials;  Freedom of scientific research;  Pharmaceutical law;  Statistics;  University self-government},
keywords={Germany;  professional standard;  research, Ethics Committees;  Germany;  Research},
references={Weber-Hassemer, K., Ethische Expertise. Gesellschaftlicher Diskurs – politische Entscheidung (2011) Grundkurs Ethik, 2. , Ach J, Bayertz K, Siep L, (eds), Mentis Verlag, Paderborn; Löwer, W., Freiheit wissenschaftlicher Forschung und Lehre (2011) Grundrechte in Deutschland – Einzelgrundrechte I, 4. , MertePapier H-J, (eds), Handbuch der Grundrechte Deutschland und Europa, C.F. Müller, München; Baer, S., Wissenschaftsfreiheit als verteilte Verantwortung (2017) Forsch Lehre, 3, pp. 214-217; Hufen, F., Wissenschaft zwischen Freiheit und Kontrolle. Zivilklauseln, Ethikkommissionen und Drittmittelkontrolle aus verfassungsrechtlicher Sicht (2017) NVwZ, 36, pp. 1265-1268; Doppelfeld, E., Hasford, J., Medizinische Ethik-Kommissionen in der Bundesrepublik Deutschland – Entstehung und Einbindung in die medizinische Forschung (2019) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; Mende, A., Frech, M., Riedel, C., Grundzüge der EU-Verordnung 536/2014 (2017) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 60, pp. 795-803; Beyerbach, H., Die Rolle von Ethik-Kommission und Bundesoberbehörde bei klinischen Arzneimittelprüfungen unter der VO Nr. 536/2014 (2016) GesR, 15, pp. 346-351; Nickel, L., Seibel, Y., Frech, M., Sudhop, T., Änderungen des Arzneimittelgesetzes durch die EU-Verordnung zu klinischen Prüfungen (2017) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 60, pp. 804-811; Sudhop, T., Grass, G., Wessler, I., Gemeinsames Pilotprojekt von Bundesoberbehörden und Ethikkommissionen zur Umsetzung der EU-Verordnung zu klinischen Prüfungen (2017) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 60, pp. 817-825; Lehmann, E., Neumann, M., Reischl, W., Tolle, I., Neuregelung des Rechts der klinischen Prüfung von Medizinprodukten und Leistungsbewertungsprüfung von In-vitro-Diagnostika in Deutschland (2010) Medizinprod J, 3, pp. 172-183; Volk, N., Klüß, C., Klinische Studien von Medizinprodukten: Übersicht und Ausblick der aktuellen Gesetzgebung und Normen (2010) Kardiotechnik, 1, pp. 12-19; Backhaus, C., Benad, N., Lau, H.-J., Pleiss, T., Die neue Verordnung (EU) Nr. 2017/745 über Medizinprodukte (2017) Medizintechnik, 4, pp. 16-21; Pigeot, I., Foraita, R., Frömke, C., Haller, B., Hoffmann, V.S., Zapf, A., Ethische Bewertung von Studien am Menschen außerhalb des regulatorischen Rahmens: nicht bindend, aber von großer Wichtigkeit (2019) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; Herbst, T., § 53 HHG Ethikkommissionen (2018) Beck’scher Online-Kommentar Hochschulrecht Hessen, , Coelln C, Thürmer M, (eds), 8, C.H. Beck, München: Edition Stand: 01.09.2018; Lipp, V., Heilversuch und medizinische Forschung (2015) Arztrecht, , Laufs A, Katzenmeier C, Lipp V, (eds), 7, Beck, München; Listl, S., (2012) Die zivilrechtliche Haftung für Fehler von Ethikkommissionen, , Springer, Heidelberg; (2013) Deklaration von Helsinki (deutsche Version), , http://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/International/Deklaration-von-Helsiniki_2013_DE.pdf; World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (2013) JAMA, 310, pp. 2191-2194; Vieth, A., (2006) Einführung in die Angewandte Ethik, , Wissenschaftliche Buchgesellschaft, Darmstadt},
correspondence_address1={Buchner, B.; Universität Bremen, Institut für Informations‑, Gesundheits- und Medizinrecht (IGMR), Universitätsallee GW 1, Germany; email: bbuchner@uni-bremen.de},
publisher={Springer Verlag},
issn={14369990},
pubmed_id={31049625},
language={German},
abbrev_source_title={Bundesgesund.blatt. Gesund.forschung. Gesund.schutz.},
document_type={Review},
source={Scopus},
}

@ARTICLE{Buchner2016660,
author={Buchner, B.},
title={Data protection and data security in digitalized medicine: Likewise an article on the E-Health Act [Datenschutz und Datensicherheit in der digitalisierten Medizin: Zugleich ein Beitrag zum eHealth-Gesetz]},
journal={Medizinrecht},
year={2016},
volume={34},
number={9},
pages={660-664},
doi={10.1007/s00350-016-4379-x},
note={cited By 1},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991694258&doi=10.1007%2fs00350-016-4379-x&partnerID=40&md5=693c10d5462f56c6e801596c763d2e95},
affiliation={Institut für Informations-, Gesundheits- und Medizinrecht (IGMR), Universität Bremen, Universitätsallee GW 1, Bremen, 28359, Germany},
references={Gesetz für sichere digitale Kommunikation und Anwendungen im Gesundheitswesen sowie zur Änderung weiterer Gesetze v. 21. 12. 2015, BGBl. I S. 2408; Zu diesen und weiteren Zielsetzungen s. BT-Dr. 18/5293, S. 1 f., 26; BT-Dr. 18/5293, S. 1, 26; Hoeren, ; Lessig, (1999), Code and Other Laws of Cyberspace; Lessig, http://harvardmagazine.com/2000/01/code-islaw-html, Harvard Magazine online v. 1. 1. 2000, Code Is Law, abrufbar unter; Bremisches Krankenhausdatenschutzgesetz (BremKHDSG) v. 25. 4. 1989 und Gesetz zum Schutz personenbezogener Daten im Gesundheitswesen (Gesundheitsdatenschutzgesetz – GDSG NW) v. 22. 2. 1994; § 9 Musterberufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte – MBO-Ä 1997; http://www.digitale-technologien.de, Kompetenzzentrum Trusted Cloud, Thesenpapier 7, S. 7, abrufbar unter; S. § 9 BDSG; § 10 Abs. 5 MBO-Ä: „Aufzeichnungen auf elektronischen Datenträgern oder anderen Speichermedien bedürfen besonderer Sicherungs- und Schutzmaßnahmen, um deren Veränderung, Vernichtung oder unrechtmäßige Verwendung zu verhindern. Ärztinnen und Ärzte haben hierbei die Empfehlungen der Ärztekammer zu beachten.“; (2013), Der Dienstleister als der „verlängerte Arm“ des Arztes; s. ausführlicher dazu Buchner, MedR; Jandt, Roßnagel, Wilke, ; Petri, (2014), Simitis (Hrsg.), BDSG, 8. Aufl, 11, Rdnr. 22; Tinnefeld/Buchner/Petri, Einführung in das Datenschutzrecht, 5. Aufl; § 11 Abs. 2 BDSG; Jandt, Roßnagel, Wilke, ; Jandt, Roßnagel, Wilke, ; Hoenike, Hülsdunk, ; Anders stellt sich die Situation im Krankenhausbereich dar: Hier stellen teils die Landeskrankenhausgesetze einen gesetzlichen Erlaubnistatbestand für das IT-Sourcing zur Verfügung, wobei die Voraussetzungen von Bundesland zu Bundesland unterschiedlich ausgestaltet sind; s. bspw. § 7 Abs. 2 GDSG NW, § 10 Abs. 1 S. 2 BremKHDSG oder auch Art. 27 Abs. 4 S. 5 Bayerisches Krankenhausgesetz (BayKrG; Gesetz zur Modernisierung der gesetzlichen Krankenversicherungen (GKV-Modernisierungsgesetz – GMG) v. 14. 11. 2003, BGBl. I S. 2190; § 3 Abs. 9 BDSG und künftig Art. 9 DSGVO; Selbst das durchaus strenge Unabhängige Landeszentrum für Datenschutz Schleswig-Holstein (ULD) bescheinigt den Regelungen zur elektronischen Gesundheitskarte, dass diese „aus Datenschutzsicht fast vorbildlich“ sind (vgl. ULD-Stellungnahme zum Referentenentwurf für ein „E-Health-Gesetz“ v. 11. 2. 2015);; aus der Literatur s. etwa auch Peters, in: KassKomm., § 291 a SGB V, Rdnr. 4 (Stand: Juni 2016): „gut gemeint und von datenschutzrechtlichen Überlegungen getragen“; § 291 a Abs. 3 S. 3 SGB V; § 291 a Abs. 3 S. 5 SGB V; § 291 a Abs. 5 S. 1 SGB V;; Schneider, Krauskopf, Soziale Krankenversicherung, Pflegeversicherung, § 291 a, Rdnr. 63 (Stand: März 2016); S. insbesondere § 291 a Abs. 5 S. 8 u. 9 SGB V;; Palandholland, A., NZS 2016, 247, 253; § 291 a Abs. 6 S. 1 u. 2 SGB V; s. dazu Peters, in: KassKomm., § 291 a SGB V, Rdnr. 18 (Stand: Juni 2016); Härting, ; (2016), pp. 1841, 1844. , s. mit Blick auf die Vorgaben der DSGVO auch: Schantz, NJW; § 291 a Abs. 1 SGB V i. d. F. v. 14. 11. 2003 mit Wirkung v. 1. 1. 2014; BT-Dr. 18/6990, S. 4; Antwort der Bundesregierung auf die Kleine Anfrage der Abgeordneten Kathrin Vogler u. a. und der Fraktion DIE Linke (Dr. 18/6788); Bohsem, http://www.kbv.de/html/418_18056.php, Süddeutsche Zeitung online v. 28. 10. 2015, Verzettelt, abrufbar unter http://www.sueddeutsche.de/wirtschaft/gesundheit-verzettelt-1.2711972, sowie (darauf Bezug nehmend) KBV, E-Health-Gesetz: Sanktionen treffen die Falschen, abrufbar unter; (2007), pp. A–1452. , S. dazu bereits DÄBl; (2015), p. 24. , Stellungnahme von Weinberg, DFZ; S. § 291 Abs. 2b S. 7 u. 14 SGB V sowie § 291 b Abs. 1 S. 11; S. § 291 Abs. 2b SGB V; http://www.aerztezeitung.de/praxis_wirtschaft/e-health/gesundheitskarte/article/909829/e-card-diesesjahr-keine-tests.html, S. Ärzte Zeitung v. 22. 4. 2016, E-Card – Dieses Jahr keine Tests mehr?; abrufbar unter; § 291 f Abs. 1 SGB V; Paland, Holland, ; Paland, Holland, ; Paland, Holland, ; http://www.wiwo.de/politik/deutschland/honorarverhandlungenwarum-sich-aerzte-und-krankenkassen-streiten/7087474.html, zum Streit zwischen KBV und GKV: Dämon, WirtschaftsWoche online v. 6. 9. 2012, Warum sich Ärzte und Krankenkassen streiten; abrufbar unter; § 87 Abs. 2a SGB V; http://institut-ba.de/ba/babeschluesse/2015-12-15_eba42.pdf, S. Beschluss des Erweiterten Bewertungsausschusses nach § 87 Abs. 4 SGB V in seiner 42. Sitzung am 15. 12. 2015 zur Änderung des Einheitlichen Bewertungsmaßstabes (EBM) mit Wirkung zum 1. 4. 2016, abrufbar unter, (letzter Abruf: 30. 6. 2016).42) § 87 Abs. 2a S. 22 SGB V},
correspondence_address1={Buchner, B.; Institut für Informations-, Gesundheits- und Medizinrecht (IGMR), Universität BremenGermany},
publisher={Springer Verlag},
issn={07238886},
language={English; German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}

@ARTICLE{Buchner2016649,
author={Buchner, B. and Hase, F.},
title={E-health, big data and co.: Informational networking of medicine as challenge for the law: Annual Meeting of the German-speaking Medical Law Teachers from May 5-7, 2016 in Bremen [E-Health, Big Data und Co Informationelle Vernetzung der Medizin als Herausforderung für das Recht: Jahrestagung der deutschsprachigen Medizinrechtslehrerinnen und Medizinrechtslehrer vom 5.–7. Mai 2016 in Bremen]},
journal={Medizinrecht},
year={2016},
volume={34},
number={9},
pages={649},
doi={10.1007/s00350-016-4382-2},
note={cited By 2},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991735137&doi=10.1007%2fs00350-016-4382-2&partnerID=40&md5=244236a4be31f7b6cdfab4931c31bb84},
affiliation={Institut für Informations-, Gesundheits- und Medizinrecht, Universität Bremen, Postfach 330440, Bremen, 28334, Germany},
references={§ 2 Abs. 1 S. 3 SGB V, §§ 5 Abs. 2, 25 Abs. 2 S. 1 Nr. 4 AMG, § 16 Abs. 1 TPG, § 3 a Abs. 2 S. 1 ESchG, § 630 a Abs. 2 BGB; Gesr; Grundlagen Und Herausforderungen Des Sozialstaats},
correspondence_address1={Buchner, B.; Institut für Informations-, Gesundheits- und Medizinrecht, Universität BremenGermany},
publisher={Springer Verlag},
issn={07238886},
language={English; German},
abbrev_source_title={Medizinrecht},
document_type={Note},
source={Scopus},
}

@ARTICLE{Buchner2015349,
author={Buchner, B.},
title={Anmerkung zu BGH, Urt. v. 23.9.2014 – VI ZR 358/13 (LG München I)},
journal={Medizinrecht},
year={2015},
volume={33},
number={5},
pages={349-350},
doi={10.1007/s00350-015-3993-3},
note={cited By 0},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938303407&doi=10.1007%2fs00350-015-3993-3&partnerID=40&md5=0f1d057aa0c2a507c0731b3b663293bd},
affiliation={IGMR, Universität Bremen, Postfach 330440, Bremen, 28334, Germany},
correspondence_address1={Buchner, B.; IGMR, Universität Bremen, Postfach 330440, Germany},
publisher={Springer Verlag},
issn={07238886},
language={German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}

@ARTICLE{Buchner2014491,
author={Buchner, B.},
title={Assignment of claims to professional dental fees - Divisible clauses [Abtretung (zahn-)ärztlicher Honorarforderungen - Teilbare Klauseln]},
journal={Medizinrecht},
year={2014},
volume={32},
number={7},
pages={491-493},
doi={10.1007/s00350-014-3746-8},
note={cited By 0},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905504611&doi=10.1007%2fs00350-014-3746-8&partnerID=40&md5=27f8a2ff20329fcd3cf043814d484a99},
affiliation={Institut für Informations-, Gesundheits- und Medizinrecht, Fachbereich Rechtswissenschaft, Universität Bremen, Universitätsallee, GW 1, 28359 Bremen, Germany},
correspondence_address1={Buchner, B.; Institut für Informations-, Gesundheits- und Medizinrecht, Fachbereich Rechtswissenschaft, Universität Bremen, Universitätsallee, GW 1, 28359 Bremen, Germany},
publisher={Springer Verlag},
issn={07238886},
language={German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}

@ARTICLE{Buchner2014493,
author={Buchner, B.},
title={Comment on the Federal Court of Justice decision dated October 10, 2013 - III ZR 325/12 (Braunschweig Higher Regional Court) [Anmerkung zu BGH, Urt. v. 10.10.2013 - III ZR 325/12 (OLG Braunschweig)]},
journal={Medizinrecht},
year={2014},
volume={32},
number={7},
pages={493-494},
doi={10.1007/s00350-014-3749-5},
note={cited By 0},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905448528&doi=10.1007%2fs00350-014-3749-5&partnerID=40&md5=0314f2d0d9945f66658eeb853d02997d},
affiliation={Institut für Informations-, Gesundheits- und Medizinrecht, Universität Bremen, Universitätsallee, GW 1, 28359 Bremen, Germany},
references={VerfG v. 23. 10. 2006 - 1 BvR 2027/02 -, MedR 2007, 351; VerfG v. 17. 7. 2013 - 1 BvR 3167/08 -, MedR 2014, 233},
correspondence_address1={Buchner, B.; Institut für Informations-, Gesundheits- und Medizinrecht, Universität Bremen, Universitätsallee, GW 1, 28359 Bremen, Germany},
publisher={Springer Verlag},
issn={07238886},
language={German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}

@ARTICLE{Buchner2014233,
author={Buchner, B.},
title={Data protection in private insurance law [Datenschutz im privaten Versicherungsrecht: GG Artt. 2 Abs. 1 i.V. mit 1 Abs. 1; VVG §213]},
journal={Medizinrecht},
year={2014},
volume={32},
number={4},
pages={233-236},
doi={10.1007/s00350-014-3670-y},
note={cited By 0},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901417818&doi=10.1007%2fs00350-014-3670-y&partnerID=40&md5=bb7bea142d38cc4b868ebcc53abad3fd},
affiliation={Institut für Informations-, Gesundheits- und Medizinrecht (IGMR), Universität Bremen, Universitätsallee, 28359 Bremen, Germany},
correspondence_address1={Buchner, B.; Institut für Informations-, Gesundheits- und Medizinrecht (IGMR), Universität Bremen, Universitätsallee, 28359 Bremen, Germany},
publisher={Springer Verlag},
issn={07238886},
language={German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}

@ARTICLE{Buchner2013337,
author={Buchner, B.},
title={Outsourcing in the medical practice - Between data security and professional confidentiality [Outsourcing in der Arztpraxis - zwischen Datenschutz und Schweigepflicht]},
journal={Medizinrecht},
year={2013},
volume={31},
number={6},
pages={337-342},
doi={10.1007/s00350-013-3427-z},
note={cited By 1},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880069225&doi=10.1007%2fs00350-013-3427-z&partnerID=40&md5=3bf36dbedd1bc2e5e198cac011d0fb5a},
affiliation={Institut für Informations-Gesundheits- und Medizinrecht, Universität Bremen, Postfach 33 04 40, 28334 Bremen, Germany},
references={Schon, S., BVerfGE, 32, p. 373. , 380; Petri, (2011) BDSG, , Simitis (Hrsg.) 7. Aufl § 11, Rdnr. 43; Menzel, (2012) Datenschutz im Gesundheitswesen, G3, p. 23. , Buchner (Hrsg.); Petri, (2011) BDSG, , Simitis (Hrsg.) 7. Aufl. § 11, Rdnr. 44; Tinnefeld, Buchner, Petri, (2012) Einführung in das Datenschutzrecht, p. 259. , Teil II, Kap. 2.7; S. etwa § 48 Abs. 2 LKHG BB, Art. 27 Abs. 4 S. 5 u. 6 BayKrG, § 10 Abs. 3 BremKHDSG oder § 9 HmbKHG; Giesen, (2012) NStZ, p. 122. , 123; Heghmanns, Niehaus, (2008) NStZ, p. 57. , 60 f. m. w. N; Giesen, (2012) NStZ, p. 122. , 128; Giesen, (2012) NStZ, p. 122. , 128; (1995) NJW, p. 2419. , LG Bonn 2420; (1993) NJW, p. 794. , LG Itzehoe; LG Bonn und LG Itzehoe, jew. a. a. O; Vgl. LG Bonn, a. a. O.; aus der Literatur s. etwa Cierniak, in: MüKo/StGB, Bd. 4, 2. Aufl. 2012, § 203, Rdnr. 51 (keine Funktionseinheit bei externen Stellen); Hartung, (2012) VersR, p. 400. , 408 ff; Heghmanns, Niehaus, (2008) NStZ, p. 57. , 58; Knauer, Brose, (2011) Medizinrecht, , Spickhoff (Hrsg.) §§ 203 ff. StGB, Rdnr. 23; Biewald, (2011) DuD, p. 867. , 867; Cierniak, (2012) MüKo/StGB, 4. , 2. Aufl. § 203, Rdnr. 123; Schünemann, (2009) LK/StGB, 6. , 12. Aufl. § 203, Rdnr. 79; Heghmanns, Niehaus, (2008) NStZ, p. 57. , 61 f; Hartung, (2012) VersR, p. 400. , 409 f. Gegen eine Verpflichtung auf Verschwiegenheit nach § 203 StGB s. jedoch Biewald, DuD 2011, 867, 867: "Straf barkeiten können nicht vereinbart werden"; Hartung, (2012) VersR, p. 400. , 409 f; S. schon oben, Fn. 19; Jandt, Roßnagel, (2011) NZS, p. 641. , 645; Kintzi, (2007) DRiZ, p. 244. , 249; Sog. Verfügbarkeitskontrolle; Anlage zu § 9 S. 1 BDSG, Ziff. 7; Zur Abgrenzung s. oben, sub I. 1; Petri, in: Simitis (Hrsg.), BDSG, 7. Aufl. 2011, § 11, Rdnr. 30; Hartung, (2012) VersR, p. 400. , 405 f.; s. schon OLG Düsseldorf, CR 1997, 536, 537; Hartung, (2012) VersR, p. 400. , 405 f; Hartung, (2012) VersR, p. 400. , 406 f; Menzel, (2012) Datenschutz im Gesundheitswesen, G7, p. 1. , Buchner (Hrsg.); Schlund, (2010) Handbuch des Arztrechts, , Laufs/Kern (Hrsg.) 4. Aufl. § 19, Rdnr. 6; Menzel, (2012) Datenschutz im Gesundheitswesen, G7, p. 1. , Buchner (Hrsg.); Gola, Schomerus, (2012) BDSG, , 11. Aufl. § 4 a, Rdnr. 34; (1991) NJW, p. 2955. , BGH; (1994) NJW, p. 2421. , OLG Düsseldorf 2422; OLG Köln, NJW 1991, 753, 754; (1991) NJW, p. 2955. , BGH 2957; ebenso auch BGH, NJW 1992, 2348, 2349; Petri, (2011) BDSG, , Simitis (Hrsg.) 7. Aufl. § 11, Rdnr. 22; Dazu schon oben bei Fn. 20; Petri, (2011) BDSG, , Simitis (Hrsg.) 7. Aufl. § 11, Rdnr. 29; S. dazu bereits oben, sub II. 2; S. soeben sub III. 2. a); Buchner, (2012) Datenschutz im Gesundheitswesen, A1, p. 15; Giring, (2011) Handbuch Medizinrecht, , Ratzel/Luxenburger (Hrsg.) 2. Aufl. § 15, Rdnr. 120; Menzel, (2012) Datenschutz im Gesundheitswesen, G2, p. 6. , Buchner (Hrsg.)},
correspondence_address1={Buchner, B.; Institut für Informations-Gesundheits- und Medizinrecht, Universität Bremen, Postfach 33 04 40, 28334 Bremen, Germany},
issn={07238886},
language={German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}

@ARTICLE{Buchner20111,
author={Buchner, B.},
title={Editorial nutrition, obesity and EU health policy},
journal={European Journal of Health Law},
year={2011},
volume={18},
number={1},
pages={1-8},
doi={10.1163/157180911X546084},
note={cited By 6},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952164889&doi=10.1163%2f157180911X546084&partnerID=40&md5=2006ec4e9ae58f33f969847ae6172760},
affiliation={Department of Law, Institut für Informations-; Gesundheits- und Medizinrecht, Bremen, Germany},
keywords={diet;  editorial;  European Union;  health care policy;  human;  obesity;  primary prevention, Diet;  European Union;  Health Policy;  Humans;  Obesity;  Primary Prevention},
references={OECD, Obesity and the Economics of Prevention: Fit not Fat 2010; Schmidt-Semisch, H., Schorb, F., Obesity interventions: Prototypes and premises (2010) Evidence-based Public Health, p. 149. , A. Gerhardus et al. eds., et seqq. in German; Lanfer, A., Hebestreit, A., Ahrens, W., Diet and Eating habits in relation to the development of obesity in children and adolescents (2010) Bundesgesundheitsbl, 53, p. 690. , in German; Summerbell, C.D., Interventions for preventing obesity in children (2005) Cochrane Database of Systematic Reviews, (3), pp. CD001871. , Art. No.:, DOI: 10.1002/14651858. CD001871.pub2; currently published in The Cochrane Database of Systematic Reviews 2010 Issue 10; http://www.oecd.org/dataoecd/45/51/38979974.pdf, OECD Health Data 2010, How Does Japan Compare, online at; http://www.mhlw.go.jp/english/wp/wp-hw/vol1/p1c3s1.html, Japanese Ministry of Health & Welfare, Annual Report on Health and Welfare 1999 Figure 3-1-1; International Comparison of Average Life Expectancy, online at; Marmot, M.G., Smith, G.D., Why are the Japanese living longer? (1989) British Medical Journal, 299 (6715), pp. 1547-1551; Böcking, W., Prevention, life expectancy and health expenditure (2007) Dtsch Med. Wochenschr, 132, pp. 2217-2220. , in German; Melby, M.K., Overview of nutrition reference and dietary recommendations in Japan: Application to nutrition policy in asian countries (2008) Asia Pac J. Clin. Nutr., 17 (S2), pp. 394-398. , See also, from an Asian perspective, emphasizing the long history of integrated and holistic approaches to nutrition in Japan; Udagawa, K., Midterm evaluation of "Health Japan 21": Focus area for the nutrition and diet (2008) Asia Pac J. Clin. Nutr., 17 (S2), pp. 445-452. , For an overview of the different Japanese Health Promotion Programs see; Shibaike, N., Utsunomiya, O., Ushiro, S., Takamiya, T., Ohuchi, A., 5. Action by Ministry of Health, Labor and Welfare National Health Promotion in the 21st century "Health Japan 21" (2002) Internal Medicine, 41 (1), pp. 70-71; Udagawa et al., supra n. 9. at 451; Marketing of Food and Non-Alcoholic Beverages to Children, Report of a WHO Forum and Technical Meeting, Oslo, 2-5 May 2006; This discussion was ended by ECJ Judgment case C-380/03 of 12 December 2006, ruling that Article 95 EC constituted an appropriate legal basis for the prohibitions of tobacco advertising and sponsorship; Proposal for a Regulation of the European Parliament and of the Council on the provision of food information to consumers, COM/2008/0040 final - COD 2008/0028; European Parliament legislative resolution of 16 June 2010 on the proposal for a regulation of the European Parliament and of the Council on the provision of food information to consumers COM 2008 0040 - C6-0052/2008-2008/ 0028 COD; http://foodwatch.de/e6380/e34762/e35853/, See e.g. the German consumer organisation foodwatch: "Scientific evidence supports traffic light colours"; available at; http://www.bll.de/themen/naehrwertinformation.html/absurde-lebensmittel- ampel, See the German food industry lobby group BLL Federation for Food Law and Food Science: ". studies have impressively documented that "traffic lights labelling" is not properly understood by consumers"; available at:, in German; Marmot, M.G., Evidence based policy or policy based evidence? Willingness to take action influences the view of evidence - Look at alcohol (2004) BMJ, 328, pp. 907-907. , See; Hagen, K., Nutritional information: Traffic light labelling is the best way to reach consumers DIW Weekly Report No. 19/2010; The European Parliament deleted in its resolution Fn. 15 Art. 34 par. 5 which allowed the use of graphical forms or symbols for the presentation of the nutrition declaration under a national scheme},
correspondence_address1={Buchner, B.; Department of Law, Institut für Informations-; Gesundheits- und Medizinrecht, Bremen, Germany},
issn={09290273},
coden={EJHLE},
pubmed_id={21409968},
language={English},
abbrev_source_title={Eur. J. Health Law},
document_type={Review},
source={Scopus},
}

@ARTICLE{Buchner20101,
author={Buchner, B.},
title={The mature patient in the Remedy Advertising Law [Der mündige Patient im Heilmittelwerberecht]},
journal={Medizinrecht},
year={2010},
volume={28},
number={1},
pages={1-6},
doi={10.1007/s00350-009-2556-x},
note={cited By 0},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-77649110650&doi=10.1007%2fs00350-009-2556-x&partnerID=40&md5=9d1e200f7679f9abf893455adfd83e71},
affiliation={Institut für Gesundheits, Medizinrecht der Universität Bremen, FB 6, Postfach 330440, 28334 Bremen, Germany},
references={(2009), Ausführlich zu all diesen und anderen Aspekten der sammelband von Klusen/Fließgarten/Nebling (Hrsg.), Informiert und selbstbe-stimmt - der mündige Bürger als mündiger Patient; Heilmittelwerbegesetz - HWG - i. d. f. v. 19.10.1994; (1999) BGH, GRuR, 179, p. 181. , Patientenwerbung; (2007) WRP, 145. , zu den erwägungen des Gesetzgebers s. Wiemers; note; Draft Report (fn. 5); note; s. insbesondere Artt. 100 g, 100i der Richtlinie i. d. f. des Kom-missionsvorschlags; (2005) Lorz, GRuR Int., 894, p. 898; (2004) Vgl. Auch Stoll, PharmaR, 100, p. 101; (2007) Willi, PharmaR, 412, p. 421; (2003) Barth, Pharm. Ind., 653, p. 655; (2003) Barth, Pharm. Ind., 572, p. 575; (2003) S. Etwa Barth, Pharm. Ind., 653, p. 655; note; (1998) Slg., , ständige Rechtsprechung; erstmals euGH I-4657, Rdnrn. 31, 37 = GRuR Int 1998, 795 - Gut springenheide; (2000) GRuR, 619. , ständige Rechtsprechung; erstmals BGH Orient-teppichmuster; (2002) Vgl. BGH, GRuR, 528, p. 529. , L-Carnitin; Oder auch ReMM-Hypothese (resourceful evaluative maximizing man); (2005) Schäfer/Ott, 4. , Lehrbuch der ökonomischen Analyse des zivilrechts Auf. s. 58 f; note; note; Thaler/Sunstein (Fn. 20), S., 32; www2.nea.org/he/heta06/images/2006pg7.pdf, so zumindest die ergebnisse einer umfrage an der university of Nebraska (Price, Are You as Good a teacher as You think; ab-ruf bar unter; Thaler/Sunstein (Fn. 20), S., 32; (1988) Vgl., 103, p. 193. , Taylor/Brown, Illusion and Well-Being: A social Psychological Perspective on Mental Health, Psychological Bulletin; (1986) The Journal of Business, 59, p. 251. , Vgl. Kahneman/Tversky, Rational Choice and the framing of Decisions; (1982) New England Journal of Medicine, 306, p. 1259. , Vgl. McNeil/Pauker/Sox/Tversky, On the elicitation of Preferences for Alternative therapies; note; (2004) Psychology and Marketing, 21, p. 159. , Vgl. Lee/Lee, the efect of Information Overload on Consumer Choice Quality in an On-Line environment; (2008) The Journal of the American Medical Informatics Association, 15, p. 484. , zum Problem der selektiven Informationswahrnehmung vgl. Keselman/Browne/Kaufman, Consumer Health Information seeking as Hypothesis testing; Schäfer/Ott (Fn. 18), S., 70; (2007) Eger/Schäfer (H R S G.), Ö Konomische Ana-lyse der Europäischen Zivilrechtsentwicklung, , Dazu und zum folgenden ausführlich Rehberg, Derstaatlicheum -gang mit Information s. 310 f; Ausführlich Rehberg (fn. 31), s. 319 f; Kommissionsvorschlag (fn. 7), s. 6},
correspondence_address1={Buchner, B.; Institut für Gesundheits, Medizinrecht der Universität Bremen, FB 6, Postfach 330440, 28334 Bremen, Germany},
issn={07238886},
language={German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}

@ARTICLE{Buchner2009201,
author={Buchner, B.},
title={Editorial: The pharmaceutical package of the European commission: Empowerment for patients?},
journal={European Journal of Health Law},
year={2009},
volume={16},
number={3},
pages={201-206},
doi={10.1163/157180909X453044},
note={cited By 1},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-70249125474&doi=10.1163%2f157180909X453044&partnerID=40&md5=99c66121e8195fd54d7b2043c75b8d5a},
affiliation={Health and Medical Law, Institute for Health and Medical Law, University of Bremen, Germany},
keywords={drug industry;  drug marketing;  editorial;  information dissemination;  prescription;  advertizing;  European Union;  health education;  human;  legal aspect, Advertising as Topic;  Drug Industry;  European Union;  Health Education;  Humans},
references={Safe, innovative and accessible medicines: a renewed vision for the harmaceutical sector, IP/08/1924, 10 December 2008; Id; Id; 83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use., , Directive 2001/; Proposal for a Directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001/83/EC on the Community code relating to medicinal products for human use, COM/2008/0663 final, 10 December 2007, 5.2 (10); Cf. Art. 100g et seqq. of the proposal; Draft report on current practices with regard to the provision of information to patients on medicinal products19 April 2007, p. 12; Schäfer, H.B., Ott, C., (2005) Lehrbuch der Ökonomischen Analyse des Zivilrechts, p. 64. , (Berlin, Heidelberg, New York: Springer); Kahneman, D., Tversky, A., Rational choice and the framing of decisions (1986) 59 The Journal of Business (, pp. 251-278; Griffin, D., Tversky, A., The weighing of evidence and the determinants of confidence (1992) 24 Cognitive Psychology, pp. 411-435; McNeil, B.J., Pauker, S.G., Sox, H.C., Tversky, A., On the elicitation of preferences for alternative therapies (1982) 306 New England Journal of Medicine, pp. 1259-1262; Schäfer, Ott, Lehrbuch, p. 69; Lee, B.K., Lee, W.N., The effect of information overload on consumer choice quality in an on-line environment (2004) 21 Psychology and Marketing, pp. 159-183; Keselman, A., Browne, A., Kaufman, D., Consumer health information seeking as hypothesis testing (2008) 15 The Journal of the American Medical Informatics Association, pp. 484-495. , on the problem of selective perception of information; COM/2008/0663 final, 5.2 (10); Art. 100d (1) (a); Art. 100d (1) (e); Citizen's Summary, Commission Communication on the Pharmaceutical Sector, 4.) LLM, UCLA},
correspondence_address1={Buchner, B.; Health and Medical Law, Institute for Health and Medical Law, University of BremenGermany},
issn={09290273},
coden={EJHLE},
pubmed_id={19788000},
language={English},
abbrev_source_title={Eur. J. Health Law},
document_type={Editorial},
source={Scopus},
}

@ARTICLE{Buchner2008127,
author={Buchner, B. and Hart, D.},
title={Research with minors in Germany},
journal={European Journal of Health Law},
year={2008},
volume={15},
number={2},
pages={127-134},
doi={10.1163/157180908X322950},
note={cited By 1},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-53549128382&doi=10.1163%2f157180908X322950&partnerID=40&md5=8e6a2c42930159c0c1e4035f706e5b06},
affiliation={Institute for Health and Medical Law (IGMR), University of Bremen},
abstract={The European GCP Directive has been implemented into German law in sect. 40 ff. AMG (German pharmaceutical law). Unlike the Directive, German pharmaceutical law basically differentiates between three constellations of clinical trials on minors: clinical trials on healthy minors, clinical trials on ill minors with an individual benefit for the individual participant, and clinical trials on ill minors without direct benefit for the individual participant, but with a so-called "group benefit". Particularly the latter possibility of conducting clinical trials on minors even if no individual benefit can be expected is not a matter of course in Germany since due to historical experiences a sceptical attitude towards clinical research on humans prevailed for a long time. German legislature has availed itself of the option granted by Article 3 of the GCP Directive to establish a higher level of protection of clinical trial subjects than the European level. © 2008 Martinus Nijhoff Publishers.},
author_keywords={Benefit/risk assessment;  Clinical trial;  Consent;  Ethic committees;  GCP directive;  Group benefit;  Minors},
keywords={clinical research;  clinical trial;  drug approval;  drug legislation;  ethics;  financial management;  Germany;  human;  informed consent;  juvenile;  legal aspect;  review;  risk benefit analysis, Adolescent;  Age Factors;  Biomedical Research;  Child;  Child Welfare;  Ethics Committees, Research;  Ethics, Research;  Humans;  Minors},
references={Kuhlmann, DÄBl. 2008, A 257 (258); http://www.paed-net.org, See; Cf. BfArM, FAQ Klinische Prüfung - Klinik - Kinderstudien; download at www.bfarm.de; 12th AMG Amendment of 30 July 2004, BGBl I, p. 2031; Ordinance of, G.C.P., (2004) BGBl I, p. 2081. , 9 August; (2004) Stellungnahme zur Forschung mit Minderjährigen, DÄBl, p. 329. , Zentrale Ethikkommission bei der Bundesärztekammer Central Ethics Committee at the German Medical Association; Jachertz, D., (2005), A 546; Kloesel/Cyran, Arzneimittelrecht, sect. 40 annot. 107; Arbeitskreis der Ethik-Kommissionen der Bundesrepublik Deutschland, Empfehlungen zur klinischen Prüfung von Arzneimitteln bei Minderjährigen, Working Group of the Ethic Committees of the Federal Republic of Germany, Recommendations for clinical drug trials on minors; Kloesel/Cyran, Arzneimittelrecht, sect. 40 annot. 112; Committee Report (Recommendations of the responsible committee of German Parliament) on sect. 41 para. 2 p. 1 AMG; printed in Kloesel/Cyran, Arzneimittelrecht, sect. 41 AMG preceding annot. 1; The procedure is regulated by sect. 40 para. 1 AMG and the GCP Ordinance based on sect. 42 para. 3 AMG; Cf. Hart, Klinische Arzneimittelprüfung, in: Rieger (ed.), Lexikon des Arztrechts, 2nd ed. 2002, last update Dec 2007, BVZ 2880, marg. no. 9 ff; Cf. Annotations of the Draft of the 12th AMG Amendment, BT-Drs. 15/2109 of 1.12.2003, sect. 42 (re. no. 28); Revised regulation of clinical drug law through the 12th AMG Amendment of 30 July 2004, BGBl I, p. 2031 of 5.8.2004; See I 2 f. above; Report of the Federal Government on experiences with the participation of ethic committees in clinical trials on the occasion of the 12th AMG Amendment, BT-Drs. 16/7703 of 20.12.2007},
correspondence_address1={Buchner, B.; Institute for Health and Medical Law (IGMR), University of BremenGermany},
issn={09290273},
coden={EJHLE},
pubmed_id={18988591},
language={English},
abbrev_source_title={Eur. J. Health Law},
document_type={Review},
source={Scopus},
}

@ARTICLE{Buchner2007313,
author={Buchner, B.},
title={Industry-sponsored medical education - In the quest for professional integrity and legal certainty},
journal={European Journal of Health Law},
year={2007},
volume={14},
number={4},
pages={313-319},
doi={10.1163/092902707X260312},
note={cited By 0},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-39849103271&doi=10.1163%2f092902707X260312&partnerID=40&md5=0aeefcee621f76356f0244c19f7cd772},
affiliation={Department Civil Law, Health and Medical Law, University of Bremen, Germany},
abstract={Industry-sponsored medical education is a much disputed issue. So far, there has been no regulatory framework which provides clear and definite rules as to whether and under what circumstances the sponsorship of medical education is acceptable. State regulation does not exist, or confines itself to a very general principle. Professional regulation, even though applied frequently, is rather vague and indefinite, raising the general question as to whether self-regulation is the right approach at all. Certainly, self-regulation by industry cannot and should not replace other regulatory approaches. Ultimately, advertising law in general and the European Directive 2001/83/EC specifically, might be a good starting point in providing legal certainty and ensuring the independence of medical education. Swiss advertising law illustrates how the principles of the European Directive could be implemented clearly and unambiguously. © 2007 Martinus Nijhoff Publishers.},
author_keywords={Advertising;  Medical education;  Professional regulation;  Self-regulation;  Sponsorship},
keywords={court;  ethics;  Europe;  health care organization;  health care policy;  law;  medical literature;  review, Advertising as Topic;  Conflict of Interest;  Education, Medical, Continuing;  Ethics, Medical;  Europe;  Financial Support;  Germany;  Government Regulation;  Humans;  Industry;  Professional Autonomy;  Switzerland;  United States},
references={Instead of continuing medical education (CME) one may also use the term continuing professional development CPD; Brennan/Rothman/Blank/Blumenthal/Chimonas/Cohen/Goldman/Kassirer/Kimball/ Naughton/Smelser, Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers, JAMA 295 (2006), 429; Id. at 431-432; NoFreeLunch, G., UK.org (www.nofreelunch-uk.org), for Germany MEZIS ("Mein Essen Zahl Ich Selbst", , www.mezis.de, For the UK see e; www.uems.net, Comprehensive information on the development and structure of continuing medical education in Europe is available at the website of the Union Européenne des Médecins Spécialistes European Union of Medical Specialists; U.E.M.S; See e.g. the Assessment criteria for continuing education meetings of the KNMG (Royal Dutch Medical Association, 2. Objectivity of the program: a) The participants are provided with objective information only. This means an objective and balanced interpretation of the educational material, especially diagnostic and therapeutic possibilities etc, b) If possible, generic names are used instead of brand names, For another example see the Criteria for Approval of CPD Events of the Royal College of Physicians of Edinburgh Guidelines, Continuing Professional Development, 1. Any commercial sponsorship or interests of the programme planner, presenters, or facilitators must be declared on the application form. 2. Any support, sponsorship or funding by commercial health care organizations has not influenced the structure or content of the educational programme; International Federation of Pharmaceutical Manufacturers & Associations; European Federation of Pharmaceutical Industries and Associations; See e.g. article 7.2 IFPMA Code: Member companies may sponsor healthcare professionals to attend events provided such sponsorship is in accordance with the following requirements: . . .• Any sponsorship provided to individual healthcare professionals must not be conditional upon an obligation to prescribe, recommend or promote any pharmaceutical product; See e.g. article 7.4 et seqq. IFPMA Code (reasonable fees; appropriate venue; moderate and reasonable as judged by local standards); Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use as amended by Directive 2002/98/EC, Directive 2004/24/EC and Directive 2004/27/EC; See e.g. Regulation 21 of the Medicines (Advertising) Regulations 1994 (as amended by the Medicines (Advertising Amendments) Regulations 2005); See e.g. the German interpretation of sec. 7 HWG (Heilmittelwerbegesetz - German Health Care Advertising Act) which implements Articles 86 et seqq. of Directive 2001/83/EC. Whereas Art. 86 et seqq. of the Directive cover all forms of sponsored educational events, sec. 7 HWG shall only cover those events which solicit specific pharmaceutical products; Heilmittelgesetz (Medicines Act); Article 33 HMG contains the general prohibition to grant pecuniary advantages or benefits; (2006) Swissmedic Journal, 1, pp. 20-45},
correspondence_address1={Buchner, B.; Department Civil Law, Health and Medical Law, University of BremenGermany},
issn={09290273},
coden={EJHLE},
pubmed_id={18431976},
language={English},
abbrev_source_title={Eur. J. Health Law},
document_type={Review},
source={Scopus},
}

@ARTICLE{Schneider2007359,
author={Schneider, W. and Buchner, B.},
title={Rejection of an expert witness because of prejudice [Ablehnung Eines Sachverständigen Wegen Besorgnis der Befangenheit]},
journal={Medizinrecht},
year={2007},
volume={25},
number={6},
pages={359-361},
doi={10.1007/s00350-007-1953-2},
note={cited By 0},
url={https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548443682&doi=10.1007%2fs00350-007-1953-2&partnerID=40&md5=6cdbd32fec28c06c9c2aa8b679567aa6},
affiliation={Universität Bremen, FB6, Postfach 330440, 28334 Bremen, Germany},
correspondence_address1={Schneider, W., München},
issn={07238886},
language={German},
abbrev_source_title={Medizinrecht},
document_type={Article},
source={Scopus},
}
